34 related articles for article (PubMed ID: 12954371)
1. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques.
Van Rompay KK; Brignolo LL; Meyer DJ; Jerome C; Tarara R; Spinner A; Hamilton M; Hirst LL; Bennett DR; Canfield DR; Dearman TG; Von Morgenland W; Allen PC; Valverde C; Castillo AB; Martin RB; Samii VF; Bendele R; Desjardins J; Marthas ML; Pedersen NC; Bischofberger N
Antimicrob Agents Chemother; 2004 May; 48(5):1469-87. PubMed ID: 15105094
[TBL] [Abstract][Full Text] [Related]
2. Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.
Botros SS; William S; Beadle JR; Valiaeva N; Hostetler KY
Antimicrob Agents Chemother; 2009 Dec; 53(12):5284-7. PubMed ID: 19704122
[TBL] [Abstract][Full Text] [Related]
3. Membrane-permeable tenofovir-di- and monophosphate analogues.
Jia X; Kullik GA; Bufano M; Brancale A; Schols D; Meier C
Eur J Med Chem; 2024 Jan; 264():116020. PubMed ID: 38086193
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study.
Del Amo J; Polo R; Moreno S; Díaz A; Martínez E; Arribas JR; Jarrín I; Hernán MA;
Ann Intern Med; 2020 Oct; 173(7):536-541. PubMed ID: 32589451
[TBL] [Abstract][Full Text] [Related]
5. A novel type of acyclic nucleoside phosphonates derived from 2-(phosphonomethoxy)propanoic acid.
Kaiser MM; Jansa P; Dračínský M; Janeba Z
Tetrahedron; 2012 May; 68(21):4003-4012. PubMed ID: 32287422
[TBL] [Abstract][Full Text] [Related]
6. Pre-exposure prophylaxis differentially alters circulating and mucosal immune cell activation in herpes simplex virus type 2 seropositive women.
Richert-Spuhler LE; Pattacini L; Plews M; Irungu E; Muwonge TR; Katabira E; Mugo N; Meyers AFA; Celum C; Baeten JM; Lingappa JR; Lund JM
AIDS; 2019 Nov; 33(14):2125-2136. PubMed ID: 31335802
[TBL] [Abstract][Full Text] [Related]
7. Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals.
Castillo-Mancilla JR; Meditz A; Wilson C; Zheng JH; Palmer BE; Lee EJ; Gardner EM; Seifert S; Kerr B; Bushman LR; MaWhinney S; Anderson PL
J Acquir Immune Defic Syndr; 2015 Apr; 68(5):495-501. PubMed ID: 25763783
[TBL] [Abstract][Full Text] [Related]
8. Immunobiological properties of selected natural and chemically modified phenylpropanoids.
Harmatha J; Zídek Z; Kmoníčková E; Smidrkal J
Interdiscip Toxicol; 2011 Mar; 4(1):5-10. PubMed ID: 21577277
[TBL] [Abstract][Full Text] [Related]
9. Interferon and its inducers--a never-ending story: "old" and "new" data in a new perspective.
De Clercq E
J Infect Dis; 2006 Sep; 194 Suppl 1(Suppl 1):S19-26. PubMed ID: 16921467
[No Abstract] [Full Text] [Related]
10. CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.
Van Rompay KK; Singh RP; Pahar B; Sodora DL; Wingfield C; Lawson JR; Marthas ML; Bischofberger N
J Virol; 2004 May; 78(10):5324-37. PubMed ID: 15113912
[TBL] [Abstract][Full Text] [Related]
11. Secretion of antiretroviral chemokines by human cells cultured with acyclic nucleoside phosphonates.
Zídek Z; Kmonícková E; Holý A
Eur J Pharmacol; 2007 Nov; 574(1):77-84. PubMed ID: 17716649
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir disoproxil fumarate.
Grim SA; Romanelli F
Ann Pharmacother; 2003 Jun; 37(6):849-59. PubMed ID: 12773076
[TBL] [Abstract][Full Text] [Related]
13. Amino Acid Ester Prodrugs of Nucleoside and Nucleotide Antivirals.
Krecmerova M
Mini Rev Med Chem; 2017; 17(10):818-833. PubMed ID: 28215138
[TBL] [Abstract][Full Text] [Related]
14. Immunobiological activity of N-[2-(phosphonomethoxy)alkyl] derivatives of N6-substituted adenines, and 2,6-diaminopurines.
Zídek Z; Potmesil P; Kmoníèková E; Holý A
Eur J Pharmacol; 2003 Aug; 475(1-3):149-59. PubMed ID: 12954371
[TBL] [Abstract][Full Text] [Related]
15. Involvement of adenosine A1 receptors in upregulation of nitric oxide by acyclic nucleotide analogues.
Zídek Z; Kmonícková E; Holý A
Eur J Pharmacol; 2004 Oct; 501(1-3):79-86. PubMed ID: 15464065
[TBL] [Abstract][Full Text] [Related]
16. Purine P1 receptor-dependent immunostimulatory effects of antiviral acyclic analogues of adenine and 2,6-diaminopurine.
Kmonícková E; Potmesil P; Holý A; Zídek Z
Eur J Pharmacol; 2006 Jan; 530(1-2):179-87. PubMed ID: 16371225
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
